BACKGROUND: Miltefosine is the first recognized oral treatment for leishmaniasis. It was first registered, in 2002, for Indian visceral leishmaniasis, and was reviewed by the present author in 2005. QUESTION: Miltefosine is now being used for the full range of clinical leishmaniasis. The present review addresses non-clinical and clinical advances since 2005. METHODS: PubMed was accessed for all articles on miltefosine from 2005 to 2008. RESULTS/ CONCLUSIONS: Miltefosine is effective and can be recommended for visceral disease in India and in Ethiopia, and for cutaneous disease in Colombia and Bolivia. For unusual forms of disease that require long periods of treatment such as diffuse cutaneous leishmaniasis and post-kala-azar dermal leishmaniasis, oral miltefosine is probably the treatment of choice.
BACKGROUND:Miltefosine is the first recognized oral treatment for leishmaniasis. It was first registered, in 2002, for Indian visceral leishmaniasis, and was reviewed by the present author in 2005. QUESTION: Miltefosine is now being used for the full range of clinical leishmaniasis. The present review addresses non-clinical and clinical advances since 2005. METHODS: PubMed was accessed for all articles on miltefosine from 2005 to 2008. RESULTS/ CONCLUSIONS:Miltefosine is effective and can be recommended for visceral disease in India and in Ethiopia, and for cutaneous disease in Colombia and Bolivia. For unusual forms of disease that require long periods of treatment such as diffuse cutaneous leishmaniasis and post-kala-azar dermal leishmaniasis, oral miltefosine is probably the treatment of choice.
Authors: Marta Gontijo Aguiar; Aline Márcia Machado Pereira; Ana Paula Fernandes; Lucas Antonio Miranda Ferreira Journal: Antimicrob Agents Chemother Date: 2010-08-16 Impact factor: 5.191
Authors: Kathryn M Dupnik; Eliana L Nascimento; Joao F Rodrigues-Neto; Tatjana Keesen; Maria Zélia Fernandes; Iraci Duarte; Selma M B Jeronimo Journal: Drug Dev Res Date: 2011-09 Impact factor: 4.360
Authors: Jiangtao Gao; Mohamed M Radwan; Francisco León; Xiaoning Wang; Melissa R Jacob; Babu L Tekwani; Shabana I Khan; Shari Lupien; Robert A Hill; Frank M Dugan; Horace G Cutler; Stephen J Cutler Journal: Med Chem Res Date: 2011-11-11 Impact factor: 1.965
Authors: Flaviana R Fernandes; Weverson A Ferreira; Mariana A Campos; Guilherme S Ramos; Kelly C Kato; Gregório G Almeida; José D Corrêa; Maria N Melo; Cynthia Demicheli; Frédéric Frézard Journal: Antimicrob Agents Chemother Date: 2013-06-24 Impact factor: 5.191
Authors: Andrés F Flórez; Daeui Park; Jong Bhak; Byoung-Chul Kim; Allan Kuchinsky; John H Morris; Jairo Espinosa; Carlos Muskus Journal: BMC Bioinformatics Date: 2010-09-27 Impact factor: 3.169